Free Trial

XBiotech Q4 2022 Earnings Report

XBiotech logo
$2.99 -0.13 (-4.17%)
As of 02/21/2025 04:00 PM Eastern

XBiotech EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
$0.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

XBiotech Earnings Headlines

Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT), a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

View XBiotech Profile

More Earnings Resources from MarketBeat